Verici Dx plc (LON:VRCI – Get Free Report) fell 10.3% on Thursday . The stock traded as low as GBX 3.23 ($0.04) and last traded at GBX 3.25 ($0.04). 638,508 shares were traded during mid-day trading, a decline of 14% from the average session volume of 741,081 shares. The stock had previously closed at GBX 3.63 ($0.05).
Verici Dx Price Performance
The stock has a 50 day moving average of GBX 3.63 and a 200-day moving average of GBX 4.79. The company has a current ratio of 4.54, a quick ratio of 8.49 and a debt-to-equity ratio of 4.65. The stock has a market capitalization of £7.88 million, a P/E ratio of -162.50 and a beta of 1.59.
About Verici Dx
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.
See Also
- Five stocks we like better than Verici Dx
- How to trade using analyst ratings
- 3 Reasons Micron Stock Is Deeply Undervalued Right Now
- 3 Healthcare Dividend Stocks to Buy
- Inflation Persists, But So Do Stock Opportunities: Rally On
- 5 discounted opportunities for dividend growth investors
- Energy Transfer Fuels the Cloud: A Natural Gas Power Play
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
